Background and aims: The prevalence of chronic benzodiazepine use in primary
usage and future intention to trial behavioural therapies as an alternative to their benzodiazepines. Based on the reported preferences of benzodiazepine users in this study, developing and evaluating GP-pharmacist collaborative services to improve the uptake of behavioural therapies as an alternative to benzodiazepines can be recommended.
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| INTRODUCTION
Benzodiazepines are widely prescribed for their hypnotic, 1 anxiolytic, 2 muscle relaxant, and antiepileptic indications. 3 Despite their common use, concerns remain over their long-term safety.
Pharmacoepidemiological data indicate that prolonged use of benzodiazepines is associated with an increased risk of falling, 4,5 therapeutic dose dependence, 6 and an increased incidence of dementia. 7 Benzodiazepine exposure is also associated with an increased risk of physical disability. 8 Recent cohort studies suggest an increased risk of exacerbations in benzodiazepine users with asthma and a higher likelihood of episodes of pneumonia and related mortality. 9, 10 A recent systemic review also highlighted an overall increased risk of all-cause mortality in benzodiazepine users. 11 Inappropriate use of benzodiazepines in Australia has been recently reported to lead to high costs of managing adverse events in residential aged care facilities. 12 In light of the well-established side effect profile of benzodiazepines, prescribing guidelines do not recommend their prolonged use.
The Royal Australian College of General Practitioners (RACGP) recommends that benzodiazepines should not be prescribed for longer than 4 weeks. 13 For patients requiring ongoing treatment, behavioural therapies such as cognitive behavioural therapy offer a promising alternative to the benzodiazepine for several conditions. For example, mounting evidence suggests that behavioural treatments produce comparable efficacy with benzodiazepines and have a longer-lasting effect in patients with insomnia. [14] [15] [16] Similarly, research evidence highlights better or equivalent efficacy profiles for behavioural therapies over benzodiazepines for managing anxiety disorder, panic disorder, and dysthymia. 17 The benefits of de-prescribing benzodiazepines have been highlighted in several studies. For example, in elderly nursing home residents, benzodiazepine withdrawal significantly improved memory and cognitive functioning compared with those who continued to take benzodiazepines; withdrawal did not give rise to anxiety, agitation, or sleeplessness. 18 Health care utilization and hospital admission costs resulting from traffic accidents and falls attributable to benzodiazepine use can be reduced through successful discontinuation 19 ; thus, benzodiazepine discontinuation can also have an economic benefit.
Despite the prescribing guidelines, the listed adverse effects of prolonged benzodiazepine use and robust evidence supporting behavioural therapies over benzodiazepines, the long-term use of 22 Although there has been a modest decline in the volume of benzodiazepine prescriptions dispensed annually, overall, there is still a high level of long-term benzodiazepine use in Australia. [23] [24] [25] For example, in the case of insomnia, almost 80% of patient presentations result in a prescription for benzodiazepine derivatives (such as temazepam, oxazepam, diazepam, and nitrazepam), and this figure has remained stable over the past 10 years. 26, 27 Both patient-and prescriber-related factors appear to be linked with prolonged benzodiazepine use. Prescribers' perceptions and attitudes have been reported to be a key factor leading to prolonged benzodiazepine use. 28 Recently, an Australian study highlighted that physicians often believe that patients taking benzodiazepines are unlikely to be willing to withdraw their medication and, thus, renew prescriptions without offering discontinuation or withdrawal plans. 29 Individual patient factors can also affect the length of benzodiazepine use; data indicate that being older, lonely, less educated, as well as having a poorer mental health profile and lower perceived general health status are associated with prolonged benzodiazepine use. 30, 31 Other patient-related factors that can influence ongoing use of benzodiazepines include beliefs and attitudes of the users towards their medication. 32 This has been proposed based on the well-known Health Belief Model (HBM), which suggests that patients' beliefs about their health issues, perceived benefits of and barriers to action, and self-efficacy explain engagement in health-promoting behaviours while the actual action is triggered by cues. 33 In fact, instruments such as the Beliefs about Medicines Questionnaire-specific version (BMQ-specific) have been designed and validated to assess patients'
beliefs and attitudes about their medications. 34 The BMQ-specific consists of two 5-item scales themed as (1) necessity and (2) concerns.
While the necessity theme assesses individuals' beliefs about the necessity of using their medication, the concerns theme evaluates their concerns about the medication (eg, side effects, fear of dependence, and among others). Thus, in the case of benzodiazepine use, it may be hypothesised that the balance between the concerns about the risk related to continued use of benzodiazepines versus the beliefs about the necessity of the medication may dictate a patients' past, current, and future decisions related to their medications, eg, attempting withdrawal, seeking safer alternatives, or continuing use. Gauging the patients' position on these opposing belief sets (necessity vs concerns) can allow health professionals to employ targeted information provision or counselling to enhance effective withdrawal. Where medication discontinuation is desirable, based on the reasoning behind the BMQ-specific, beliefs that foster medication discontinuation (higher-risk perception about the medication and a lesser perceived necessity for use) could serve as a triggering point at which patients can be empowered and pragmatic strategies offered to facilitate withdrawal. In support of this notion, a qualitative study in patients with anxiety indicated that strong beliefs around the necessity of using benzodiazepines and a lower level of concern about long-term use were associated with resistance to benzodiazepine discontinuation. 35 Similarly, another qualitative study reported that individuals with higher concerns about the risk of taking benzodiazepines were more likely to attempt ceasing the medication of their own volition and were often more interested in trying behavioural interventions. 36 Exploratory work mapping such beliefs about benzodiazepines and intention to continue use is clearly required for successful discontinuation trials.
Although there has been considerable research to characterize such individual sociodemographic and belief factors, there are, to date, few real-life studies available on patients' perceptions around benzodiazepine use and withdrawal. Minimal attention has been paid to the complexity of factors affecting the decision making involved in withdrawing benzodiazepines. Successful and sustained withdrawal behaviours require a prior intention, and past behaviour may contribute to this future intention. 37 In most research reporting trials of benzodiazepine weaning off, the patients' willingness to withdraw benzodiazepines and intention or readiness to adopt alternative therapies are assumed but not explored. [38] [39] [40] It is not surprising that in many of these reported trials, benzodiazepine discontinuation rates remain less than 65%, with low-response and high-dropout rates. [38] [39] [40] Patients' willingness to stop the medication and try behavioural therapies might be a key factor that affects successful discontinuation.
Therefore, the present study primarily aimed to investigate the association of participants' sociodemographic variables and beliefs about the benzodiazepine, with their benzodiazepine use behaviours, including past (previous benzodiazepine withdrawal attempts), current (long-term benzodiazepine use, ie, using benzodiazepines for at least 1 year), as well as future behaviours (willingness to trial behavioural substitutes in the future). Additionally, the study aimed to explore the patients' source preference for information about alternative behavioural therapies. The findings of this study will potentially inform effective, patient-centred, and evidence-based interventions for reducing long-term benzodiazepine use and disseminating behavioural therapies with greater scope and sustainability.
2 | METHODS
| Study design
Given that this study aimed to explore real-life behaviour, a point of purchase survey of benzodiazepine consumers was used. This method allows researchers to study consumer behaviour for informing interventions and policy development. 41, 42 The survey questionnaire was developed by reviewing relevant literature, 35, 43, 44 
| Participants
Pharmacies throughout the Australian state of New South Wales 
| Analysis
Completed survey questionnaires were assigned a code before initiating the analysis. Data were entered into the IBM SPSS Statistics package for Windows, Version 22.0 (Released 2013, Armonk, New York:
IBM Corp), and entered data were checked for normality using the Kolmogorov-Smirnov (K-S) test 46 as well as through visual inspection of histograms. 47 Descriptive analyses were conducted to examine the demographic characteristics of participants. Correlation coefficients (Spearman's correlation coefficient or Phi coefficient for two binary variables) were used to describe (1) associations between current long-term benzodiazepine use (using benzodiazepines for at least 1 year) and the following variables: age, sex, level of education, benzodiazepines being used, length of action of the benzodiazepine, and reason for taking the benzodiazepine; (2) associations between the BMQ score (concerns and necessity themes) and long-term benzodiazepine use (current behaviours), benzodiazepine withdrawal attempt (past behaviours), and preference for behavioural therapies (future behaviours); and (3) associations between past, current, and future intended behaviours. Finally, binary logistic regression was conducted to determine whether past benzodiazepine withdrawal attempts and future preference for behavioural therapies differed with demographic or beliefs-related variables that were significant in the correlation analysis or previous literature. [48] [49] [50] [51] All tests were two-sided with a significance level of 0.05.
| RESULTS
The results are outlined with reference to our study's stated aims;
these included exploring the association of participant's benzodiazepine usage behaviours with their sociodemographic characteristics and medication-related beliefs. A secondary aim of the study was to confirm participants' preferences for information sources on alternative behavioural techniques. Accordingly, in the results section, firstly participants' demographics and then their scores on the BMQ-specific questionnaire 34 are presented. This is followed by presenting associations between the sociodemographics and BMQ scores with participants' benzodiazepine usage behaviours, which are presented in sequence: past (previous withdrawal attempt), current (long-term use of benzodiazepine), and future (intention to try behavioural alternatives)
behaviours. Finally, participants' preferred sources of information for behavioural therapies are descriptively reported.
A total of 75 participants (67% female) out of 107 approached (70% response rate) were recruited for this study from 12 different pharmacies across NSW. Of these 12 pharmacies, 10 were medium-sized Table 1 .
| Past benzodiazepine use behaviours (withdrawal attempts)
In the sample, 47% (n = 35) of the participants had attempted to withdraw the benzodiazepine, and in these cases, sudden cessation of the benzodiazepine was the most commonly reported strategy applied to withdraw the medication. The reported reasons for attempting benzodiazepine withdrawal included concerns about health (49%), fear of Using benzodiazepines for at least 1 year 50 (67) Reason for benzodiazepine use
Using benzodiazepine for sleep disorders 44 (59) Using benzodiazepine for psychiatric disorders 23 (31) Using benzodiazepine for pain 5
Using benzodiazepine for other problems 3 (4) developing dependence (40%), doctors' suggestion (37%), and other reasons (17%). Details about the reasons and strategies for withdrawing the benzodiazepine are presented in Table 2 .
In a binary logistic regression analysis, none of the variables evaluated (age, sex, level of education, benzodiazepines being used, length of action of the benzodiazepine, and reason for taking the benzodiazepine) were significantly associated with a benzodiazepine withdrawal attempt. There was no significant correlation between the BMQ themes and past withdrawal attempts.
| Current long-term benzodiazepine use
There was a moderately strong negative correlation (r s Table 3 .
We observed no significant correlation between participants' age, sex, benzodiazepines being used, duration of action of the benzodiazepine, or their reason for taking the benzodiazepine with current longterm benzodiazepine use. Trying an antidepressant 1
Trying behavioural strategies 1
Following pharmacists' advice 1
Taking the benzodiazepine when needed 1
Reasons for attempted benzodiazepine withdrawal were derived by having participants choose from multiple choice options presented to them with the questions. Strategies used for withdrawing the benzodiazepines were derived by having participants write open-ended answers in space provided after the questions. The variables presented in the table are thematically collated. 
| Future benzodiazepine use behaviours
In the sample, about two thirds (n = 48) of the participants were not willing to consider behavioural therapies as a substitution for their benzodiazepines (only 27/75 participants were interested in behavioural therapies). In these cases, participants' lack of confidence about the efficacy of behavioural therapies and their lack of time to try behavioural therapies were the main two reasons for not considering behavioural therapies. The reported reasons for not considering behavioural therapies are highlighted in Table 4 .
We observed no statistically significant association between past benzodiazepine use behaviours (withdrawal attempts) and the future intentions of trialling behavioural therapies (Table 3 ).
There was a weak (r s [75] = 0.297, p = 0.010) relationship between the BMQ concerns theme and future preference for behavioural therapies (Table 3) . Interestingly, binary logistic regression revealed that participants using benzodiazepines for sleep disorders were more likely to be in the "interested in behavioural therapies" group (odds ratio [OR] = 3.138; 95% confidence interval [CI],
1.037-9.492) ( Table 5 ). Indeed, of the 27 participants who were interested to consider behavioural therapies, 20 participants were those who reported using the benzodiazepine for managing sleep disorders.
3.4 | Source preference for information about alternative behavioural therapies Participants' perception that behavioural therapies take longer time to produce effect 11 (23) Participants' perception that seeing a psychologist is costly 9 (19) Other reason 5 (10)
Reasons for not preferring behavioural therapies were derived by having participants choose from multiple choice options presented to them with the questions. itate decisions about discontinuing benzodiazepines; they report a significantly lower-necessity score and higher-concerns score after the intervention. 54 In our study, the results indicate that concerns about the medication are related to both lower current long-term use and higher preference for future behavioural alternatives. In fact, health concerns and the fear of being addicted were the most commonly reported reasons for a benzodiazepine withdrawal attempt, as
shown in other studies as well. 55 Therefore, discussing concerns in an individualised manner to the patient may be effective in helping patients decide to discontinue long-term benzodiazepine use. Since there is considerable evidence around applying patients' beliefs about medication to explore or improve their adherence to a set treatment plan, 56, 57 it can be suggested that patients' beliefs about their benzodiazepine can also be used to predict adherence to a set treatment withdrawal plan.
Sudden cessation of benzodiazepines was the most commonly used strategy for withdrawing the benzodiazepine, and this approach is a distinct departure from clinical guidelines recommending gradual dose reduction for patients on benzodiazepines for longer than 3 to 4 weeks to minimise or avoid withdrawal symptoms. 58, 59 Sudden cessation of benzodiazepines in long-term users may result in lifethreatening seizures. 58 These disparities between the guidelines and current withdrawal strategies may reflect that either participant opted to self-withdraw without health professional advice, or participants possibly received only ad-hoc advice from their GPs (or primary care physicians or family physicians) or dispensing pharmacists to withdraw the benzodiazepine. In the latter instance, a clear step-by-step plan may not have been offered during the GP or pharmacist consultation, given that these health professionals would be well aware of the pharmacological consequences of sudden cessation and would be able to refer to published guidelines on how to help patients discontinue benzodiazepines in a tapered manner. [60] [61] [62] Given that even minimal interventions by primary health care professionals can be effective, 63 primary care professionals should be upskilled and upresourced so as to be able to provide concrete direction when recommending discontinuation of benzodiazepines. A meta-analysis suggests that gradual dose reduction combined with psychological interventions has better outcomes compared with a gradual dose reduction alone. 64 Appropriate deprescribing plans, adjunctive psychotherapy, and careful monitoring (eg, using withdrawal assessment tools) should be key elements in the benzodiazepine discontinuation process initiated by GPs, who are the main prescribers of benzodiazepines. 58, 65, 66 Evidence-based pragmatic guidelines for de-prescribing benzodiazepines and practice toolkits may be required to facilitate this.
A majority of the participants were not interested in behavioural therapies, contrary to previous studies generally demonstrating that patients favour non-pharmacological therapies over pharmacotherapies. 67, 68 This inconsistency relative to other studies may be due to small sample size and selection bias in our study. The inconsistency might also be related to the fact that the participants may not have been experienced or informed about behavioural treatments earlier. 67, 69 Greater public awareness about the efficacy of behavioural therapies may be a prudent step for addressing this issue, eg, through public health campaigns given that benzodiazepines have been implicated in vehicle accidents. 70, 71 Another strategy to improve the uptake of behavioural therapies could be to introduce internet-delivered behavioural therapy services. Studies suggest that internet-based behavioural therapies have the potential to be time-efficient and cost-effective as well as quite acceptable for patients. 72, 73 Interestingly, participants with sleep problems in this study were more likely to prefer behavioural treatment, which supports and further extends previous research. 74, 75 These patients can be specifically targeted for behavioural intervention in primary care settings.
Since a majority of the participants identified doctors as their first choice for learning more about behavioural therapies, GPs need to take the initiative to make patients familiar with the behavioural therapies. However, physicians cite time paucity, high workload, lack of skills in behavioural treatment, and limited accessibility to behavioural therapy providers as the barriers to reduce benzodiazepine use and introduce behavioural interventions in general practice setting. 76, 77 Introducing other health care professionals co-located within GP practice centres to support GPs for educating patients about behavioural therapies may help to overcome some of these issues. 29 In a qualitative Australian study, GPs acknowledged the role of other health professionals in facilitating successful benzodiazepine cessation. 44 In the current study, following GPs, pharmacists were the second preferred source of information for behavioural therapies. Thus, a collaborative approach with pharmacists could be an option where they can support GPs in withdrawing benzodiazepines and providing behavioural therapies. 78 Community pharmacists also have the opportunity to counsel patients at the point of purchase; in the case of patients with repeat prescriptions, community pharmacists see benzodiazepine users even more frequently. At these opportunities, pharmacists can discuss the 
| Strengths and limitations
The small sample size may be a limitation of this study. power. 84 However, the study may have been underpowered to demonstrate lower-strength correlation at the same significance level and power. There is a possibility of selection bias, as individuals who have successfully withdrawn their benzodiazepines were not recruited for this study. Further, the questions used in this study to explore participants' willingness to withdraw and preferences for behavioural therapies were customised for this study. However, the questionnaire was developed by reviewing the previous literature and was facevalidated by psychology, sleep, and pharmacy practice researchers.
Given this part of the questionnaire measured a set of diverse issues (past behaviour of withdrawing, actual daily use of benzodiazepine, and future intentions to try alternatives to benzodiazepine use), internal consistency was not measured, as behaviour and intention constructs are in themselves quite different and these questions also had different response items. Past behaviours appeared less important based on our data, and current behaviours are verifiable through pharmacy prescription records. Therefore, it may be suggested that a fuller set of items with comparable response sets around intended future behaviours with respect to benzodiazepines should be constructed and tested psychometrically. This would be useful for future research and is certainly a limitation in our study. The questionnaire did not ask explicitly about participants' readiness or current intention to withdraw from the benzodiazepine. Exploring participants' belief was limited to BMQ-specific rather than using the more comprehensive exploration of belief sets, for example, using variables included in models such as the HBM. Lastly, there is a possibility for response bias (eg, strong beliefs about the necessity of benzodiazepines, low concerns, and social desirability). 
